Hsbc Holdings PLC Has $8.25 Million Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Hsbc Holdings PLC trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 8.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 228,030 shares of the specialty pharmaceutical company's stock after selling 22,334 shares during the quarter. Hsbc Holdings PLC owned approximately 0.41% of Supernus Pharmaceuticals worth $8,246,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC purchased a new position in Supernus Pharmaceuticals in the fourth quarter valued at $52,000. Headlands Technologies LLC grew its position in shares of Supernus Pharmaceuticals by 203.0% during the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock valued at $55,000 after acquiring an additional 1,015 shares during the period. Newbridge Financial Services Group Inc. acquired a new stake in Supernus Pharmaceuticals in the fourth quarter valued at approximately $72,000. Finally, Venturi Wealth Management LLC purchased a new stake in Supernus Pharmaceuticals in the 4th quarter worth $92,000.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. StockNews.com upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 17th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Insider Activity at Supernus Pharmaceuticals

In other news, SVP Jonathan Rubin sold 927 shares of the firm's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,915.30. This represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. 9.30% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Stock Performance

SUPN traded up $0.39 during trading on Friday, reaching $32.84. The company's stock had a trading volume of 359,758 shares, compared to its average volume of 494,466. The company's fifty day moving average price is $31.86 and its 200-day moving average price is $34.96. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of 30.69 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.